GlassScriptPhysician profile
Steven Margolin
NPI 1598768475
$445.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $83.91 · 2021: $47.89 · 2022: $12.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64.26 | 2020-2021 | |
| Novo Nordisk INC | $50.93 | 2019-2020 | |
| Abbvie INC. | $44.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.67 | 2019 | |
| Amgen INC. | $25.23 | 2019 | |
| Lilly USA, LLC | $20.14 | 2019 | |
| Sanofi Pasteur INC. | $17.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.21 | 2019 | |
| Astellas Pharma US INC | $16.12 | 2019 | |
| Bolton Medical INC | $14.90 | 2021 | |
| Horizon Therapeutics Plc | $14.60 | 2020 | |
| Merck Sharp & Dohme LLC | $14.24 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.85 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.43 | 2019 | |
| Genentech USA, INC. | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Margolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.